Governance at a Glance

Chair
Member
Board Members Audit Compensation Nominating and Corporate Governance

Scott A. Kelly, M.D.

Nader Z. Pourhassan, Ph.D.

Jordan G. Naydenov 1

Lishomwa C. Ndhlovu, M.D., Ph.D. 1

Dr. Harish Seethamraju 1

Tanya Durkee Urbach 1 , 2

1 Independent Director
2 Lead Independent Director

Committee Charters

Scott A. Kelly, M.D.

Scott A. Kelly, M.D.

Dr. Kelly was named Chairman of the Board in December 2018 and he has served as a director since April 2017. Dr. Kelly was named to the non-executive position of Chief Science Officer of the Company in July 2019. He was appointed Chief Medical Officer and Head of Business Development in April 2020. Prior to leaving clinical medicine to focus on CytoDyn, he served at Atlanta-based Resurgens Orthopaedics since 2002, including as Director of the Safety Council since 2013 and as Medical Director of the Resurgens Orthopaedics' Spine Center since 2007. He is a fellow of the American Board of Physical Medicine and Rehabilitation and a diplomate of the American Academy of Physical Medicine and Rehabilitation. He has received numerous honors including being named as America's Best Physicians in 2018 by the National Consumer Advisory Board, Leading Physicians of the World in 2018 by the International Association of Healthcare Professionals (IAHCP), America's Most Honored Professionals in 2018 and 2019 by The American Registry, America's Best Physicians in 2016, 2017, 2018, and 2019 by The National Consumer Advisory Board, "Top Doctor" in 2015, 2016, 2017, and 2019 by Castle Connolly, and "Top Doctor" by Atlanta Magazine in 2016, 2017 2018, and 2019. He is the author of What I've Learned from You: The Lessons of Life Taught to a Doctor by His Patients. He received his BA in Psychology from Emory University, his medical doctorate from Medical College of Georgia and completed his medical residency at Emory University.

Nader Z. Pourhassan, Ph.D.

Nader Z. Pourhassan, Ph.D.

Dr. Pourhassan received his Bachelor of Science from Utah State University in 1985, his Master of Science from Brigham Young University in 1990 and his Ph.D. in Mechanical Engineering from the University of Utah in 1998. Dr. Pourhassan has authored three books. His 20 years of business development experience set the stage for him to transform a publicly traded biotech company on the brink of bankruptcy, into a company on the cusp of potentially obtaining FDA approval for its first drug. If granted approval, the drug called leronlimab (PRO 140) could change the treatment paradigms in both HIV and metastatic cancer.

Dr. Pourhassan joined CytoDyn (CYDY) in 2008 as Chief Operating Officer and by September 2012, was appointed President and CEO. He was responsible for identifying significant opportunities for leronlimab, and single handedly raised enough capital for CytoDyn to complete an acquisition of PRO 140 from Progenics Pharmaceuticals. Dr. Pourhassan has overseen the rapid preclinical and clinical developments of leronlimab (PRO 140) as a therapy for HIV, from Phase 2 development into successful completion of Phase 3 trials. This includes the oversight of the development of trial protocols and interaction with the U.S. Food and Drug Administration (FDA). Dr. Pourhassan also opened the door for exploring leronlimab (PRO 140) for other indications. Most notably, he has been involved in the clinical developments of leronlimab in indications for triple-negative breast cancer, 22 different solid tumor cancers, GvHD, NASH and several different populations of COVID-19.

To advance the drug development of leronlimab for all these indications, Dr. Pourhassan raised capital for CytoDyn of approximately $400 million in the last 10 years.

Jordan G. Naydenov

Jordan G. Naydenov

Mr. Naydenov has been a Director of CytoDyn since June 2009. For more than 20 years, Mr. Naydenov has been actively involved in innovative developments in a variety of fields, ranging from sports, fitness, & health to robotic technology. Since 2001, Mr. Naydenov has served as the Vice President and Director of Milara Incorporated, a leading and multi-faceted company that specializes in wafer-handling robotics, semiconductor systems, and surface mount technologies. In 2006, Mr. Naydenov became the Treasurer of Milara Inc., and additionally began serving as the Director of Milara International, the international representative of Diamond and Equipe brands of Semiconductor Robotics & Systems. Since then, Mr. Naydenov has expanded his experience in innovative developments and industries, with his most recent endeavor beginning in 2017 as the founder of the natural health care product company, Pure Care Pro LLC.

Lishomwa C. Ndhlovu, M.D., Ph.D.

Lishomwa C. Ndhlovu, M.D., Ph.D.

Appointed to Weill Cornell Medicine in 2019 as Professor of Immunology in Medicine and Neuroscience, Dr. Ndhlovu has served on the Company’s Scientific Advisory Board since July 2020. Before joining Weill Cornell Medicine, Dr. Ndhlovu was a Professor at the University of Hawaii from 2011 to 2019, where he retains an adjunct appointment. As Co-leader of the $26.5 million NIH—Martin Delaney Collaboratory for HIV Cure “HOPE.”, he is a recognized expert in basic and complex immunology and immunotherapy research. He has focused much of his work on confronting the challenges of HIV and aging, addressing molecular mechanism of HIV and COVID-19 pathogenesis, complications and persistence. Dr. Ndhlovu received his M.D. from the University of Zambia and his Ph.D. from Tohoku University in Japan and is an elected Fellow of the American Academy of Microbiology. He brings a deep understanding of the central nervous system aspects of HIV and research expertise in major arenas in which the Company is conducting clinical trials of its drug product candidate.

Dr. Harish Seethamraju

Dr. Harish Seethamraju

Dr. Seethamraju is the Medical Director for the Mount Sinai Lung Transplantation Program. Before joining Mount Sinai, Dr. Seethamraju was the Medical Director of Lung Transplantation at Montefiore Medical Center in New York. He also served as the Medical Director of the Advanced Lung Disease/Lung Transplant Program at Beth Israel Medical Center in Newark, NJ. In his early career, he was an Associate Professor of Medicine at the University of Kentucky College of Medicine and previously served as the Medical Director of the Lung Transplant Program, Associate Professor of Medicine at the Houston Methodist Hospital/Baylor College of Medicine. He is recognized as an international expert in lung transplantation and advanced lung failure. His research focuses primarily on clinical aspects of advanced lung disease and lung transplantation. He has conducted numerous clinical research trials and co-authored dozens of articles in his field. As part of his focus on lung diseases, Dr. Seethamraju recently participated as an investigator in two of the Company’s clinical trials of leronlimab in the treatment of COVID-19 patients. Dr. Seethamraju received his medical training at Gandhi Medical College in Hyderabad, India, a pulmonary fellowship at Interfaith Medical Center in Brooklyn, New York, and a pulmonary and critical care fellowship at Baylor College of Medicine.

Tanya Durkee Urbach

Tanya Durkee Urbach

Ms. Urbach is currently Partner/Head of Family Office for Eagle Bay Advisors, which provides family office and investment advisory services, and also provides corporate governance and corporate finance advice to Dynepic, Inc., which provides an integrated platform to power immersive training programs for companies and U.S. military forces. From November 2020 through March 31, 2021, Ms. Urbach was a sole practitioner advising broker-dealers, investment advisers and their professionals. From January 2019 through October 2020, she was a shareholder at the law firm Markun, Zusman, Freniere & Compton in Portland, Oregon. She served as General Counsel for Paulson Investment Company, LLC, a registered broker-dealer that provides investment banking services to the Company from time to time, from July 2015 until January 2019, providing advice regarding corporate governance, securities regulatory compliance, corporate finance, and other legal and securities-related issues. Ms. Urbach earned her bachelor’s degree at University of Oregon and her law degree at Lewis & Clark Law School. She served on the Executive Committee of the Oregon State Bar Securities Regulation Section from 2007 through 2015 and 2019 to the present. She brings extensive training and expertise in the conduct of securities offerings, securities litigation, corporate finance and business growth, corporate governance, and other corporate business and legal issues to the Board.